Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆.
Sign Up to like & getrecommendations! Published in 2017 at "Oral oncology"
DOI: 10.1016/j.oraloncology.2017.09.017
Abstract: OBJECTIVE Nivolumab is the first drug to demonstrate a survival benefit for platinum-refractory recurrent or metastatic head and neck cancer. We performed a cost-utility analysis to assess the economic value of nivolumab as compared to… read more here.
Keywords: recurrent metastatic; metastatic head; cost; cost effectiveness ... See more keywords
Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice
Sign Up to like & getrecommendations! Published in 2017 at "Chemotherapy"
DOI: 10.1159/000475803
Abstract: Aims: To evaluate the effectiveness of nivolumab as second-line treatment compared to standard therapy with docetaxel in adult patients with non-small cell lung cancer (NSCLC) in clinical practice. Methods: This is an observational, retrospective cohort… read more here.
Keywords: second line; line treatment; effectiveness nivolumab; patients treated ... See more keywords